Page 19 - தகவல்கள் பாதுகாப்பு கண்காணிப்பு பலகை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

NOXXON Announces Data Safety Monitoring Board Validates NOX-A12 Highest Dose in Phase 1/2 Brain Cancer Trial NOXXON Pharma N.V. (Paris:ALNOX) (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today that an independent Data Safety Monitoring Board (DSMB) has confirmed that the highest dose of NOX-A12 in combination with radiotherapy in the ongoing Phase 1/2 study in patients with brain cancer is safe and that the trial should continue as planned. Regulatory News: The study investigates three dose regimens of NOX-A12 (200, 400 and 600 mg/week), each combined with external-beam radiotherapy in newly diagnosed brain cancer patients. The DSMB recommendation to proceed followed the analysis of safety data stipulated in the study protocol after all three patients in the third – and last – cohort completed at least four weeks of treatment at the highest dose.

Aram mangasarianMerck sharp dohme corpEuronext growth parisData safety monitoring boardMerck sharpதகவல்கள் பாதுகாப்பு கண்காணிப்பு பலகைமெர்க் கூர்மையான